JPRN-UMIN000005262已完成未知
Candesartan-Based Treatment for Variability Lowering of Individual Blood Pressure and Heart Rate at Home Study - Candesartan-Based Treatment for Variability Lowering of Individual Blood Pressure and Heart Rate (CAVALIER) at Home Study
Department of Internal Medicine Division of Cardio-vascular Medicine, Kurume University School of Medicine0 个研究点目标入组 928 人开始时间: 2011年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 928
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Poorly controlled hypertension (DBP greater than 120mmHg) 2. Poorly controlled diabetic patients (HbA1c greater than 9.0%) 3. Gout or serum uric acid greater than 8.0mg/dL 4. Renal insufficiency (serum creatinine greater than 2.0mg/dl) 5. Hyperkalimia (K greater than 5.5 mmol/L) 6. Liver damage (gamma-GTP or ALT greater than 3 x normal upper limit) 7. Endocrine secondary hypertension 8. Malignant hypertension 9. Contraindication for candesartan, amlodipine, orHCTZ 10. Prescribed ARB/CCB tablet or ARB/HCTZ tablet before registration
研究者
相似试验
进行中（未招募）
不适用
Candesartan added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months. - CAN-DHFSymptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patientsMedDRA version: 9.1Level: LLTClassification code 10019279Term: Heart failureMedDRA version: 9.1Level: LLTClassification code 10052337Term: Diastolic dysfunctionEUCTR2007-003070-26-DETakeda Pharma GmbH
已完成
3 期
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.Heart FailureNCT00775840Takeda22
进行中（未招募）
不适用
Candesartan added Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters.An open, non-controlled and multicentre trialHeart failureEUCTR2004-003962-14-DETakeda Pharma GmbH
已完成
不适用
Candesartan may prevent aneurysmal changes in the residual native aorta after thoracic aortic aneurysm surgeryThoracic aortic aneurysmJPRN-UMIN000000756Graduate School of Medicine, Tohoku University150
已完成
3 期
DIabetic Retinopathy Candesartan TrialsType 2 DiabetesNCT00252694AstraZeneca4,717